Ludovico Abenavoli
Overview
Explore the profile of Ludovico Abenavoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
308
Citations
3761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gambardella M, Luigiano C, La Torre G, Scarlata G, Luzza F, Abenavoli L
Minerva Gastroenterol (Torino)
. 2025 Mar;
PMID: 40048148
Liver cirrhosis, marked by fibrosis and nodular regeneration, triggers a cascade of events resulting in portal hypertension (PH) and, subsequently, hepatic decompensation in its final stages. PH, arising from increased...
2.
Gambardella M, Abenavoli L
Br J Hosp Med (Lond)
. 2025 Feb;
86(2):1-5.
PMID: 39998141
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and is linked to metabolic syndrome components such as insulin resistance and obesity. In 2020, the term...
3.
Scarcella M, Scarpellini E, De Rosa S, Umbrello M, Petroni G, Monti R, et al.
Nutrients
. 2025 Feb;
17(3).
PMID: 39940354
Background: Malnutrition and muscle weakness are highly prevalent in critically admitted patients. To overcome sarcopenia and muscle weakness, physical activity and neuromuscular electric stimulation have been introduced with limited efficacy....
4.
Scarlata G, Abenavoli L
Expert Rev Gastroenterol Hepatol
. 2025 Feb;
19(2):85-88.
PMID: 39907629
No abstract available.
5.
Luigiano C, Di Leo M, Magistroni M, Iabichino G, Arena M, Consolo P, et al.
Rev Recent Clin Trials
. 2025 Feb;
PMID: 39901672
Background: Anastomotic leakages are one of the most frequent complications of gastroesophageal surgery with a high mortality. Objective: This study aimed to assess the efficacy and safety of endoscopic therapy...
6.
Abenavoli L, Guzzi P
J Gastrointestin Liver Dis
. 2024 Dec;
33(4):444-447.
PMID: 39733309
No abstract available.
7.
Scarlata G, Ismaiel A, Gambardella M, Leucuta D, Luzza F, Dumitrascu D, et al.
Medicina (Kaunas)
. 2024 Nov;
60(11).
PMID: 39597039
Liver cirrhosis is a chronic, progressive condition characterized by fibrosis and architectural distortion of the liver, leading to impaired liver function and severe complications. Accurately predicting these complications is crucial...
8.
Scarpellini E, Scarcella M, Tack J, Scarlata G, Zanetti M, Abenavoli L
Antioxidants (Basel)
. 2024 Nov;
13(11).
PMID: 39594528
The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. The human gut bacterial microbiota has been extensively proven to participate in human metabolism,...
9.
Abenavoli L, Spagnuolo R, Scarlata G, Gambardella M, Boccuto L, Mendez-Sanchez N, et al.
Life (Basel)
. 2024 Oct;
14(10).
PMID: 39459526
Background: Inflammatory bowel disease (IBD) is characterized by persistent inflammation and is often associated with metabolic dysfunction-associated steatotic liver disease (MASLD). IBD patients are at risk of developing MASLD due...
10.
Tauil R, Golono P, de Lima E, de Alvares Goulart R, Landgraf Guiguer E, Bechara M, et al.
Pharmaceuticals (Basel)
. 2024 Oct;
17(10).
PMID: 39458995
Metabolic-Associated Fatty Liver Disease (MAFLD) is a clinical-pathological scenario that occurs due to the accumulation of triglycerides in hepatocytes which is considered a significant cause of liver conditions and contributes...